Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3641-3650

  Voo, Kui S ^a   Bover, Laura ^a   Harline, Megan L ^a   Vien, Long T ^a   Facchinetti, Valeria ^a   Arima, Kazuhiko ^b   Kwak, Larry W ^a   Liu, Yong J ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAGA UNIVERSITY   (Japan)

^c BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD134 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELL PROTEIN; INTERLEUKIN 10; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX40; PROTEIN ICOS; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE; CELL PROLIFERATION; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MICE; PROTEIN BINDING; RECEPTORS, OX40; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84885121967     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202752     Document Type: Article

References (39)

1. Dougan, M., and G. Dranoff. 2009. Immune therapy for cancer. Annu. Rev. Immunol. 27:83-117.
2. Kantoff, P. W., C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, et al; IMPACT Study Investigators. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363:411-422.
3. Schuster, S. J., S. S. Neelapu, B. L. Gause, J. E. Janik, F. M. Muggia, J. P. Gockerman, J. N. Winter, C. R. Flowers, D. A. Nikcevich, E. M. Sotomayor, et al. 2011. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29:2787-2794.
4. Schwartzentruber, D. J., D. H. Lawson, J. M. Richards, R. M. Conry, D. M. Miller, J. Treisman, F. Gailani, L. Riley, K. Conlon, B. Pockaj, et al. 2011. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364:2119-2127.
5. Ahmadzadeh, M., L. A. Johnson, B. Heemskerk, J. R. Wunderlich, M. E. Dudley, D. E. White, and S. A. Rosenberg. 2009. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114:1537-1544.
6. Barrat, F. J., D. J. Cua, A. Boonstra, D. F. Richards, C. Crain, H. F. Savelkoul, R. de Waal-Malefyt, R. L. Coffman, C. M. Hawrylowicz, and A. O'Garra. 2002. In vitro generation of interleukin 10-producing regulatory CD4 (+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1) - and Th2-inducing cytokines. J. Exp. Med. 195:603-616.
7. Quezada, S. A., K. S. Peggs, T. R. Simpson, and J. P. Allison. 2011. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev. 241:104-118.
8. Roncarolo, M. G., S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212:28-50.
9. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-562.
10. Yaguchi, T., H. Sumimoto, C. Kudo-Saito, N. Tsukamoto, R. Ueda, T. Iwata-Kajihara, H. Nishio, N. Kawamura, and Y. Kawakami. 2011. The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 93:294-300.
11. Zou, W., and L. Chen. 2008. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8:467-477.
12. + T cells in metastases from melanoma patients. J. Clin. Invest. 121:2350-2360.
13. Nishikawa, H., and S. Sakaguchi. 2010. Regulatory T cells in tumor immunity. Int. J. Cancer 127:759-767.
14. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949.
15. Ishida, T., T. Ishii, A. Inagaki, H. Yano, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda. 2006. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 66:5716-5722.
16. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133:775-787.
17. Fu, S., N. Zhang, A. C. Yopp, D. Chen, M. Mao, D. Chen, H. Zhang, Y. Ding, and J. S. Bromberg. 2004. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 2 precursors. Am. J. Transplant. 4:1614-1627.
18. Horwitz, D. A., S. G. Zheng, and J. D. Gray. 2003. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J. Leukoc. Biol. 74:471-478.
19. Vence, L., A. K. Palucka, J. W. Fay, T. Ito, Y. J. Liu, J. Banchereau, and H. Ueno. 2007. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 104:20884-20889.
20. Wang, H. Y., D. A. Lee, G. Peng, Z. Guo, Y. Li, Y. Kiniwa, E. M. Shevach, and R. F. Wang. 2004. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20:107-118.
21. Jarnicki, A. G., J. Lysaght, S. Todryk, and K. H. Mills. 2006. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 177:896-904.
22. Choi, B. K., J. S. Bae, E. M. Choi, W. J. Kang, S. Sakaguchi, D. S. Vinay, and B. S. Kwon. 2004. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J. Leukoc. Biol. 75:785-791.
23. Hirschhorn-Cymerman, D., G. A. Rizzuto, T. Merghoub, A. D. Cohen, F. Avogadri, A. M. Lesokhin, A. D. Weinberg, J. D. Wolchok, and A. N. Houghton. 2009. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 206:1103-1116.
24. Piconese, S., B. Valzasina, and M. P. Colombo. 2008. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205:825-839.
25. Shimizu, J., S. Yamazaki, T. Takahashi, Y. Ishida, and S. Sakaguchi. 2002. Stimulation of CD25 (+) CD4 (+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3:135-142.
26. Stephens, G. L., R. S. McHugh, M. J. Whitters, D. A. Young, D. Luxenberg, B. M. Carreno, M. Collins, and E. M. Shevach. 2004. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J. Immunol. 173:5008-5020.
27. Valzasina, B., C. Guiducci, H. Dislich, N. Killeen, A. D. Weinberg, and M. P. Colombo. 2005. Triggering of OX40 (CD134) on CD4 (+) CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105:2845-2851.
28. Ito, T., Y. H. Wang, O. Duramad, S. Hanabuchi, O. A. Perng, M. Gilliet, F. X. Qin, and Y. J. Liu. 2006. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc. Natl. Acad. Sci. USA 103:13138-13143.
29. So, T., and M. Croft. 2007. Cutting edge: OX40 inhibits TGF-beta-and antigendriven conversion of naive CD4 T cells into CD25+Foxp3+ T cells. J. Immunol. 179:1427-1430.
30. Vu, M. D., X. Xiao, W. Gao, N. Degauque, M. Chen, A. Kroemer, N. Killeen, N. Ishii, and X. C. Li. 2007. OX40 costimulation turns off Foxp3+ Tregs. Blood 110:2501-2510.
31. Duan, W., T. So, and M. Croft. 2008. Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigenspecific Foxp3+ T regulatory cells. J. Immunol. 181:8650-8659.
32. Sugamura, K., N. Ishii, and A. D. Weinberg. 2004. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat. Rev. Immunol. 4:420-431.
33. Croft, M., T. So, W. Duan, and P. Soroosh. 2009. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol. Rev. 229:173-191.
34. Redmond, W. L., C. E. Ruby, and A. D. Weinberg. 2009. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit. Rev. Immunol. 29:187-201.
35. Gough, M. J., C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg. 2008. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68:5206-5215.
36. Weinberg, A. D., C. Thalhofer, N. Morris, J. M. Walker, D. Seiss, S. Wong, M. K. Axthelm, L. J. Picker, and W. J. Urba. 2006. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J. Immunother. 29:575-585.
37. Xie, F., Q. Wang, Y. Chen, Y. Gu, Q. Shi, Y. Ge, G. Yu, H. Wu, Y. Mao, X. Wang, et al. 2006. Characterization and application of two novel monoclonal antibodies against human OX40:costimulation of T cells and expression on tumor as well as normal gland tissues. Tissue Antigens 67:307-317.
38. Kroemer, A., X. Xiao, M. D. Vu, W. Gao, K. Minamimura, M. Chen, T. Maki, and X. C. Li. 2007. OX40 controls functionally different T cell subsets and their resistance to depletion therapy. J. Immunol. 179:5584-5591.
39. Takahashi, Y., R. Tanaka, N. Yamamoto, and Y. Tanaka. 2008. Enhancement of OX40-induced apoptosis by TNF coactivation in OX40-expressing T cell lines in vitro leading to decreased targets for HIV type 1 production. AIDS Res. Hum. Retroviruses 24:423-435.